<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011 Dec;32(23):2999-3054. [320 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21873419&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W, ESC Committee for Practice Guidelines (CPG), Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Kristensen SD, Widimsky P, McGregor K, Sechtem U, Tendera M, Hellemans I, Gomez JL, Silber S, Funck-Brentano C, Kristensen SD, Andreotti F, Benzer W, Bertrand M, Betriu A, De Caterina R, DeSutter J, Falk V, Ortiz AF, Gitt A, Hasin Y, Huber K, Kornowski R, Lopez-Sendon J, Morais J, Nordrehaug JE, Silber S, Steg PG, Thygesen K, Tubaro M, Turpie AG, Verheugt F, Windecker S, Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007 Jul;28(13):1598-660.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Anemia, unspecified  (285.9); Aortocoronary bypass for heart revascularization, not otherwise specified  (36.10); Diagnostic ultrasound of heart  (88.72); Electrocardiogram  (89.52); End stage renal disease  (585.6); Heart failure, unspecified  (428.9); Hemorrhage, unspecified  (459.0); Other acute and subacute forms of ischemic heart disease, other  (411.89); Thrombocytopenia, unspecified  (287.5)"/><FieldValue Value="MSH: Acute Coronary Syndrome ; Adenosine ; Adrenergic beta-Antagonists ; Anemia ; Angiography ; Angioplasty, Balloon ; Angioplasty, Balloon, Coronary ; Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Anticoagulants ; Aspirin ; Biological Markers ; Blood Coagulation Factor Inhibitors ; Calcium Channel Blockers ; Cardiac Surgical Procedures ; Coronary Angiography ; Coronary Artery Bypass ; Diabetes Mellitus ; Drug-Eluting Stents ; Echocardiography ; Electrocardiography ; Enoxaparin ; Exercise Test ; Fibrinolytic Agents ; Health Services for the Aged ; Heart Failure ; Hemorrhage ; Heparin ; Heparin, Low-Molecular-Weight ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Kidney Failure, Chronic ; Medical History Taking ; Myocardial Revascularization ; Nitrates ; Peptide Fragments ; Percutaneous Coronary Intervention ; Piperazines ; Platelet Aggregation Inhibitors ; Polysaccharides ; Proton Pump Inhibitors ; Purinergic P2Y Receptor Antagonists ; Recombinant Proteins ; Rehabilitation ; Risk Assessment ; Risk Factors ; Secondary Prevention ; Smoking Cessation ; Stents ; Thiophenes ; Thrombocytopenia ; Ticlopidine "/><FieldValue Value="MTH: Adrenergic beta-Antagonists ; Aldosterone Antagonists ; Anemia ; angiogram ; Angioplasty, Balloon ; Angioplasty, Balloon, Coronary ; Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Anticoagulants ; Aspirin ; Biological Markers ; bivalirudin ; Calcium Channel Blockers ; Cardiac Surgery procedures ; Cessation of smoking ; Coronary angiography ; CORONARY ARTERIOSCLEROSIS ; Coronary Artery Bypass Surgery ; Diabetes Mellitus ; Echocardiography ; Electrocardiogram ; Electrocardiography ; Exercise stress test ; Fibrinolytic Agents ; Heart failure ; Hemorrhage ; Heparin ; Heparin, Low-Molecular-Weight ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Kidney Failure, Chronic ; Nitrates ; Percutaneous Coronary Intervention ; Platelet Aggregation Inhibitors ; Platelet Glycoprotein IIb/IIIA Inhibitors [MoA] ; Polysaccharides ; Proton Pump Inhibitors ; Rehabilitation therapy ; Risk Assessment ; risk factors ; ST segment elevation (finding) ; Stent, device ; thrombocytopenia ; Troponin I measurement ; Troponin measurement ; Troponin T Assay "/><FieldValue Value="PDQ: acetylsalicyclic acid ; anemia ; angiography ; biological markers ; enoxaparin ; heparin ; thrombocytopenia "/><FieldValue Value="SNOMEDCT_US: Acute coronary syndrome  (394659003); Adenosine  (108502004); Adenosine  (35431001); Aldosterone antagonist  (346312000); Aldosterone antagonist  (372603003); Anemia  (271737000); Angiography  (77343006); Angiography kit  (468962002); Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Anticoagulant  (372862008); Anticoagulant  (81839001); Aspirin  (387458008); Aspirin  (7947003); beta-Blocking agent  (33252009); beta-Blocking agent  (373254001); Bivalirudin  (129498009); Bivalirudin  (400610005); Calcium channel blocker  (373304005); Calcium channel blocker  (48698004); Clopidogrel  (108979001); Clopidogrel  (386952008); Coronary angiography  (33367005); Coronary arteriosclerosis  (53741008); Coronary artery bypass graft  (232717009); Coronary artery bypass graft  (67166004); Coronary artery bypass graft  (90205004); Coronary artery stent  (705643001); CT angiography  (418272005); Diabetes mellitus  (73211009); Drug eluting stent  (411191007); Echocardiography  (40701008); Electrocardiographic procedure  (29303009); End stage renal disease  (46177005); End stage renal disease  (90688005); Enoxaparin  (108984007); Enoxaparin  (372562003); Exercise tolerance test  (165079009); Fondaparinux  (395236007); Fondaparinux  (708189008); Heart failure  (84114007); Hemorrhage  (131148009); Hemorrhage  (50960005); Heparin  (372877000); Heparin  (84812008); Heparin  (96382006); HMG-CoA reductase inhibitor  (372912004); HMG-CoA reductase inhibitor  (96302009); Low molecular weight heparin  (373294004); Low molecular weight heparin  (87233003); Myocardial revascularization  (174911007); Myocardial revascularization  (275227003); Myocardial revascularization  (81266008); Nitrate salt  (89119000); Operation on heart  (64915003); Percutaneous coronary intervention  (415070008); Platelet count below reference range  (302215000); Platelet count below reference range  (415116008); Polysaccharide  (71544008); Prasugrel  (443129001); Prasugrel  (443312008); Proton pump inhibitor  (108665006); Proton pump inhibitor  (372525000); Recombinant protein  (407073003); Rehabilitation therapy  (52052004); Risk assessment  (225338004); Risk factor  (80943009); Secondary prevention  (315234002); ST segment elevation  (164931005); ST segment elevation  (76388001); Stent  (65818007); Thrombolytic  (303960004); Thrombolytic  (372742009); Ticlopidine  (108971003); Ticlopidine  (386950000); Troponin I measurement  (121870001); Troponin measurement  (105000003); Troponin T measurement  (121871002)"/><FieldValue Value="SPN: HEPARIN ; STENT, CORONARY "/><FieldValue Value="UMD: Physiologic Monitor Modules, Electrocardiography  (20-771); Scanning Systems, Ultrasonic, Cardiac  (17-422); Stents  (15-784); Stents, Vascular, Coronary  (18-237)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Acute coronary syndromes without persistent ST-segment elevation&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Emergency Medicine" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Pharmacology" /><FieldValue Value="Surgery" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Emergency Medical Technicians/Paramedics" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To summarize and evaluate all available evidence, at the time of the writing process, on a particular issue with the aim of assisting physicians in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome, as well as the risk&amp;ndash;benefit ratio of particular diagnostic or therapeutic means &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To present recommendations on the management of patients with suspected acute coronary syndromes without persistent ST-segment elevation &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with suspected acute coronary syndromes without persistent ST-segment elevation&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis/Risk Assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clinical history and symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;12-lead electrocardiogram (ECG) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of additional ECG leads (V&lt;sub&gt;3R&lt;/sub&gt;, V&lt;sub&gt;4R&lt;/sub&gt;, V&lt;sub&gt;7&amp;ndash;V9&lt;/sub&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Measurement of biomarkers (e.g., cardiac troponin T or I) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of established risk scores for prognosis and bleeding (e.g., Global Registry of Acute Coronary Events [GRACE], Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology [ACC]/American Heart Association [AHA] guidelines [CRUSADE]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Echocardiogram &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Coronary angiography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Coronary computed tomography (CT) angiography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Noninvasive stress test for inducible ischaemia &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment/Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Anti-ischaemic agents, such as beta-blockers, nitrates, and non-dihydropyridine calcium channel blockers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antiplatelet agents, such as aspirin, P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel), proton pump inhibitors, and glycoprotein IIb/IIIa receptor blockers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anticoagulants, such as fondaparinux, enoxaparin, unfractionated heparin, low-molecular-weight heparins, and bivalirudin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of a proton pump inhibitor in combination with dual anti-platelet therapy (DAPT) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Invasive management&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Timing of revascularization &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Coronary angiography &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Percutaneous coronary interventions &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Use of drug-eluting stents &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Coronary artery bypass surgery &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Special considerations in the following patients groups and circumstances&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Elderly &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patients with chronic kidney disease &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Diabetic patients &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patients with heart failure &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patients with anaemia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patients with bleeding complications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patients with thrombocytopenia &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Secondary Prevention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Long-term beta-blocker therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lipid-lowering therapy (statins) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Angiotensin-converting enzyme (ACE) inhibitors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Angiotensin receptor blockers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Aldosterone antagonists &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Sensitivity, specificity, and predictive value of diagnostic tests&lt;/li&gt;&#xA;    &lt;li&gt;Death (mortality) rates&lt;/li&gt;&#xA;    &lt;li&gt;Myocardial infarction rates&lt;/li&gt;&#xA;    &lt;li&gt;Incidence of angina and stroke&lt;/li&gt;&#xA;    &lt;li&gt;Rate of re-infarction and re-hospitalization &lt;/li&gt;&#xA;    &lt;li&gt;Rate of thrombosis and major bleeding&lt;/li&gt;&#xA;    &lt;li&gt;Symptom relief&lt;/li&gt;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The PubMed database was searched from May 2011 over the 20 previous years. Specific search terms used included: acute coronary syndrome, angioplasty, aspirin, bivalirudin, bypass surgery, chest pain unit, clopidogrel, diabetes, enoxaparin, fondaparinux, guidelines, heparin, non-ST-elevation, myocardial infarction, prasugrel, stent, ticagrelor, troponin, unstable angina.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Data derived from multiple randomized clinical trials or meta-analyses.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Data derived from a single randomized clinical trial or large non-randomized studies.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consensus of opinion of the experts and/or small studies, retrospective studies, registries.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk&amp;ndash;benefit ratio. Estimates of expected health outcomes for larger populations were included, where data exist. The levels of evidence and the strengths of recommendation of particular treatment options were weighed and graded according to predefined scales (see the &quot;Rating Scheme for the Strength of the Evidence&quot; and the &quot;Rating Scheme for the Strength of the Recommendations&quot; fields).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The class A level of evidence in this document is based primarily on randomized, double-blind studies of adequate size using contemporary adjunctive treatment and endpoints that are not subject to observer bias, such as death and myocardial infarction. These studies were considered to represent the greatest weight of evidence. Studies that were randomized, but not double blind, and/or studies using less robust endpoints (e.g., refractory ischaemia or need for revascularization) were considered to confer a lower weight of evidence. If only smaller studies were available, meta-analyses were used. However, even the largest controlled trials do not cover all aspects seen in real life. Therefore, some recommendations are derived from subset analyses of larger trials, in the absence of sufficiently powered independent studies.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Members of this Task Force were selected by the European Society of Cardiology (ESC) to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for diagnosis, management, and/or prevention of a given condition according to ESC Committee for Practice Guidelines (CPG) policy.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Classes of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Classes of Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Classes of Recommendations&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Suggested Wording to Use&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Is recommended/is indicated&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class II&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;em&gt;Weight of evidence/opinion is in favour of usefulness/efficacy.&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Should be considered&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;em&gt;Class IIb&lt;/em&gt;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;em&gt;Usefulness/efficacy is less well established by evidence/opinion.&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;May be considered&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Is not recommended&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The European Society of Cardiology (ESC) Guidelines undergo extensive review by the Committee for Practice Guidelines (CPG) and external experts. After appropriate revisions, it is approved by all of the experts involved in the Task Force. The finalized document is approved by the CPG for publication in the &lt;em&gt;European Heart Journal&lt;/em&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions for the classes of recommendations (I-III) and the levels of evidence (A-C) can be found at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Prognosis Assessment&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for Diagnosis and Risk Stratification&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with a suspected non-ST-segment elevation acute coronary syndrome (NSTE-ACS), diagnosis and short-term ischaemic/bleeding risk stratification should be based on a combination of clinical history, symptoms, physical findings, electrocardiogram (ECG) (repeated or continuous ST monitoring), and biomarkers. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Lev et al., 2003; Thygesen et al., 2007; Thygesen et al., 2010; Hamm et al., 1997; Antman et al., 1996; Scirica et al., 2009; Akkerhuis et al., 2001)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ACS patients should be admitted preferably to dedicated chest pain units or coronary care units. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt; (Hasin et al., 2005)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It is recommended to use established risk scores for prognosis and bleeding (e.g., Global Registry of Acute Coronary Events [GRACE], Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology [ACC]/American Heart Association [AHA] guidelines [CRUSADE]). &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Fox et al., 2006; Subherwal et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A 12-lead ECG should be obtained within 10 min after first medical contact and immediately read by an experienced physician. This should be repeated in the case of recurrence of symptoms, and after 6&amp;ndash;9 and 24 h, and before hospital discharge. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Diercks et al., 2006; Thygesen et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Additional ECG leads (V&lt;sub&gt;3R&lt;/sub&gt;, V&lt;sub&gt;4R&lt;/sub&gt;, V&lt;sub&gt;7&lt;/sub&gt;&amp;ndash;V&lt;sub&gt;9&lt;/sub&gt;) are recommended when routine leads are inconclusive. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt; (Thygesen et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Blood has to be drawn promptly for troponin (cardiac troponin T or I) measurement. The result should be available within 60 min. The test should be repeated 6&amp;ndash;9 h after initial assessment if the first measurement is not conclusive. Repeat testing after 12&amp;ndash;24 h is advised if the clinical condition is still suggestive of acute coronary syndrome (ACS). &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Thygesen et al., 2010; Hamm et al., 1997)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A rapid rule-out protocol (0 and 3 h) is recommended when highly sensitive troponin tests are available (see Figure 5 in the original guideline document). &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Keller et al., 2009; Reichlin et al., 2009; Weber et al., 2011)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An echocardiogram is recommended for all patients to evaluate regional and global left ventricular (LV) function and to rule in or rule out differential diagnoses. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Coronary angiography is indicated in patients in whom the extent of coronary artery disease (CAD) or the culprit lesion has to be determined. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Coronary computed tomography (CT) angiography should be considered as an alternative to invasive angiography to exclude ACS when there is a low to intermediate likelihood of CAD and when troponin and ECG are inconclusive. &lt;strong&gt;(Class of recommendation IIa, level of evidence B)&lt;/strong&gt; (Hoffmann et al., 2009; Rubinshtein et al., 2007; Meijboom et al., 2007; Hollander et al., 2009; Chang et al., 2008)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients without recurrence of pain, normal ECG findings, negative troponins tests, and a low risk score, a noninvasive stress test for inducible ischaemia is recommended before deciding on an invasive strategy. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Kwong et al., 2003; Nyman et al., 1993; Amsterdam et al., 2002)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Anti-ischaemic Agents&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Anti-ischaemic Drugs&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Oral or intravenous nitrate treatment is indicated to relieve angina; intravenous nitrate treatment is recommended in patients with recurrent angina and/or signs of heart failure. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients on chronic &amp;beta;-blocker therapy admitted with ACS should be continued on &amp;beta;-blocker therapy if not in Killip class &amp;ge;III. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Miller et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Oral &amp;beta;-blocker treatment is indicated in all patients with LV dysfunction without contraindications. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (&quot;Randomised trial of intravenous atenolol,&quot; 1986; &quot;Metoprolol in acute myocardial infarction [MIAMI],&quot; 1985; Miller et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Calcium channel blockers are recommended for symptom relief in patients already receiving nitrates and &amp;beta;-blockers (dihydropyridines type), and in patients with contraindications to &amp;beta;-blockade (benzothiazepine or phenylethylamine type). &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Lubsen &amp;amp; Tijssen, 1987)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Calcium channel blockers are recommended in patients with vasospastic angina. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Intravenous &amp;beta;-blocker treatment at the time of admission should be considered for patients in a stable haemodynamic condition (Killip class &amp;lt;III) with hypertension and/or tachycardia. &lt;strong&gt;(Class of recommendation IIa, level of evidence C)&lt;/strong&gt; (Chen et al., 2005)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Nifedipine, or other dihydropyridines, are not recommended unless combined with &amp;beta;-blockers. &lt;strong&gt;(Class of recommendation III, level of evidence B)&lt;/strong&gt; (Lubsen &amp;amp; Tijssen, 1987)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Antiplatelet Agents&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Oral Antiplatelet Agents&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Aspirin should be given to all patients without contraindications at an initial loading dose of 150&amp;ndash;300 mg, and at a maintenance dose of 75&amp;ndash;100 mg daily long-term regardless of treatment strategy. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Antithrombotic Trialists' [ATT] Collaboration et al., 2009; Mehta et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A P2Y&lt;sub&gt;12&lt;/sub&gt; inhibitor should be added to aspirin as soon as possible and maintained over 12 months, unless there are contraindications such as excessive risk of bleeding. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Yusuf et al., 2001; Wiviott et al., 2007; Wallentin et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A proton pump inhibitor (preferably not omeprazole) in combination with dual antiplatelet therapy (DAPT) is recommended in patients with a history of gastrointestinal haemorrhage or peptic ulcer, and appropriate for patients with multiple other risk factors (&lt;em&gt;Helicobacter pylori&lt;/em&gt; infection, age &amp;ge;65 years, concurrent use of anticoagulants or steroids). &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (O'Donoghue et al., 2009; Abraham et al., 2010; Bhatt et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Prolonged or permanent withdrawal of P2Y&lt;sub&gt;12&lt;/sub&gt; inhibitors within 12 months after the index event is discouraged unless clinically indicated. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Ticagrelor (180-mg loading dose, 90 mg twice daily) is recommended for all patients at moderate-to-high risk of ischaemic events (e.g., elevated troponins), regardless of initial treatment strategy and including those pre-treated with clopidogrel (which should be discontinued when ticagrelor is commenced). &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Wallentin et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Prasugrel (60-mg loading dose, 10-mg daily dose) is recommended for P2Y&lt;sub&gt;12&lt;/sub&gt;-inhibitor-na&amp;iuml;ve patients (especially diabetics) in whom coronary anatomy is known and who are proceeding to percutaneous coronary intervention (PCI) unless there is a high risk of life-threatening bleeding or other contraindications.* &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Wiviott et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clopidogrel (300-mg loading dose, 75-mg daily dose) is recommended for patients who cannot receive ticagrelor or prasugrel. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Yusuf et al., 2001; Mehta et al., 2001; Steinhubl et al., 2002)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A 600-mg loading dose of clopidogrel (or a supplementary 300-mg dose at PCI following an initial 300-mg loading dose) is recommended for patients scheduled for an invasive strategy when ticagrelor or prasugrel is not an option. &lt;strong&gt;(Class of recommendation I, level of evidence B&lt;/strong&gt;) (Mehta et al., 2010; Montalescot et al., 2006; Snoep et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A higher maintenance dose of clopidogrel 150 mg daily should be considered for the first 7 days in patients managed with PCI and without increased risk of bleeding. &lt;strong&gt;(Class of recommendation IIa, level of evidence B)&lt;/strong&gt; (Mehta et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Increasing the maintenance dose of clopidogrel based on platelet function testing is not advised as routine, but may be considered in selected cases. &lt;strong&gt;(Class of recommendation IIb, level of evidence B)&lt;/strong&gt; (Price et al., 2011)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Genotyping and/or platelet function testing may be considered in selected cases when clopidogrel is used. &lt;strong&gt;(Class of recommendation IIb, level of evidence B)&lt;/strong&gt; (Mega et al., 2010; Breet et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients pre-treated with P2Y&lt;sub&gt;12&lt;/sub&gt; inhibitors who need to undergo non-emergent major surgery (including coronary artery bypass graft [CABG]), postponing surgery at least for 5 days after cessation of ticagrelor or clopidogrel, and 7 days for prasugrel, if clinically feasible and unless the patient is at high risk of ischaemic events should be considered. &lt;strong&gt;(Class of recommendation IIa, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Ticagrelor or clopidogrel should be considered to be (re-) started after CABG surgery as soon as considered safe. &lt;strong&gt;(Class of recommendation IIa, level of evidence B)&lt;/strong&gt; (Held et al., 2011)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The combination of aspirin with a non-steroidal anti-inflammatory drug (NSAID) (selective cyclo-oxygenase [COX-2] inhibitors and non-selective NSAID) is not recommended. &lt;strong&gt;(Class of recommendation III, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Prasugrel is in the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/percutaneous-coronary-interventions.aspx&quot; title=&quot;ESC Web site&quot;&gt;Guidelines on Revascularisation&lt;/a&gt; given a IIa recommendation as the overall indication including clopidogrel-pre-treated patients and/or unknown coronary anatomy. The class I recommendation here refers to the specifically defined subgroup.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Glycoprotein (GP) IIb/IIa Inhibitors&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The choice of combination of oral antiplatelet agents, a GP IIb/IIIa receptor inhibitor, and anticoagulants should be made in relation to the risk of ischaemic and bleeding events. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Among patients who are already treated with DAPT, the addition of a GP IIb/IIIa receptor inhibitor for high-risk PCI (elevated troponin, visible thrombus) is recommended if the risk of bleeding is low. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Kastrati et al., 2006; Valgimigli et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Eptifibatide or tirofiban added to aspirin should be considered prior to angiography in high-risk patients not preloaded with P2Y&lt;sub&gt;12&lt;/sub&gt; inhibitors. &lt;strong&gt;(Class of recommendation IIa, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In high-risk patients eptifibatide or tirofiban may be considered prior to early angiography in addition to DAPT, if there is ongoing ischaemia and the risk of bleeding is low. &lt;strong&gt;(Class of recommendation IIb, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;GP IIb/IIIa receptor inhibitors are not recommended routinely before angiography in an invasive treatment strategy. &lt;strong&gt;(Class of recommendation III, level of evidence A)&lt;/strong&gt; (Giugliano et al., 2009; Neumann et al., 2003)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;GP IIb/IIIa receptor inhibitors are not recommended for patients on DAPT who are treated conservatively. &lt;strong&gt;(Class of recommendation III, level of evidence A)&lt;/strong&gt; (Stone et al., &quot;Routine,&quot; 2007; Giugliano et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Anticoagulants&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Anticoagulants&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Anticoagulation is recommended for all patients in addition to antiplatelet therapy. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Harrington et al., 2008; Eikelboom et al., 2000)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The anticoagulation should be selected according to both ischaemic and bleeding risks, and according to the efficacy&amp;ndash;safety profile of the chosen agent. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Fondaparinux (2.5 mg subcutaneously daily) is recommended as having the most favourable efficacy&amp;ndash;safety profile with respect to anticoagulation. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Simoons et al., 2004; Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators et al., 2006)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the initial anticoagulant is fondaparinux, a single bolus of unfractionated heparin (UFH) (85 IU/kg adapted to activated clotting time [ACT], or 60 IU in the case of concomitant use of GP IIb/IIIa receptor inhibitors) should be added at the time of PCI. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (FUTURA/OASIS-8 Trial Group et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Enoxaparin (1 mg/kg twice daily) is recommended when fondaparinux is not available. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators et al., 2006; Petersen et al., 2004)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If fondaparinux or enoxaparin are not available, UFH with a target activated partial thromboplastin time (aPTT) of 50&amp;ndash;70 s or other low-molecular-weight heparins (LMWHs) at the specific recommended doses are indicated. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Bivalirudin plus provisional GP IIb/IIIa receptor inhibitors are recommended as an alternative to UFH plus GP IIb/IIIa receptor inhibitors in patients with an intended urgent or early invasive strategy, particularly in patients with a high risk of bleeding. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (White et al., 2008; Stone et al., 2006; Stone et al., &quot;Bivalirudin,&quot; 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In a purely conservative strategy, anticoagulation should be maintained up to hospital discharge. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators et al., 2006; Cohen et al., 1997; &quot;Long-term low-molecular-mass heparin,&quot; 1999; &quot;Low-molecular-weight heparin,&quot; 1996)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Discontinuation of anticoagulation should be considered after an invasive procedure unless otherwise indicated. &lt;strong&gt;(Class of recommendation IIa, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Crossover of heparins (UFH and LMWH) is not recommended. &lt;strong&gt;(Class of recommendation III, level of evidence B)&lt;/strong&gt; (Harrington et al., 2008; Hirsh &amp;amp; Raschke, 2004; Petersen et al., 2004)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Coronary Revascularization&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Invasive Evaluation and Revascularization&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An invasive strategy (within 72 h after first presentation) is indicated in patients with:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;At least one high-risk criterion (see Table 9 in the original guideline document) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recurrent symptoms &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Task Force on Myocardial Revascularization of the European Society of Cardiology [ESC] et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Urgent&lt;/strong&gt; coronary angiography (&amp;lt;2 h) is recommended in patients at very high ischaemic risk (refractory angina, with associated heart failure, life-threatening ventricular arrhythmias, or haemodynamic instability). &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt; (Task Force on Myocardial Revascularization of the ESC et al., 2010; Fox et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An &lt;strong&gt;early&lt;/strong&gt; invasive strategy (&amp;lt;24 h) is recommended in patients with a GRACE score &amp;gt;140 or with at least one primary high-risk criterion. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Mehta et al., 2009; Sorajja et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Non-invasive documentation of inducible ischaemia is recommended in low-risk patients without recurrent symptoms before deciding for invasive evaluation. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Nyman et al., 1993; Amsterdam et al., 2002; Task Force on Myocardial Revascularization of the ESC et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The revascularization strategy (&lt;em&gt;ad-hoc&lt;/em&gt; culprit lesion PCI/multivessel PCI/CABG) should be based on the clinical status as well as the disease severity, i.e., distribution and angiographic lesion characteristics (e.g., SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery [SYNTAX] score), according to the local 'Heart Team' protocol. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;As there are no safety concerns related to the use of drug-eluting stents (DESs) in ACS, DESs are indicated on an individual basis taking into account baseline characteristics, coronary anatomy, and bleeding risk. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Kaiser et al., 2010; Greenhalgh et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;PCI of non-significant lesions is not recommended. &lt;strong&gt;(Class of recommendation III, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Routine invasive evaluation of low-risk patients is not recommended. &lt;strong&gt;(Class of recommendation III, level of evidence A)&lt;/strong&gt; (Task Force on Myocardial Revascularization of the ESC et al., 2010; O'Donoghue et al., 2008)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Special Populations and Conditions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Elderly Patients&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Because of the frequent atypical presentation, elderly patients (&amp;gt;75 years) should be investigated for NSTE-ACS at low level of suspicion. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt; (Brieger et al., 2004; Alexander et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Treatment decisions in the elderly (&amp;gt;75 years) should be made in the context of estimated life expectancy, co-morbidities, quality of life, and patient wishes and preferences. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt; (Alexander et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Choice and dosage of antithrombotic drugs should be tailored in elderly patients to prevent the occurrence of adverse effects. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt; (Alexander et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Elderly patients should be considered for an early invasive strategy with the option of possible revascularization, after careful weighing up of the risks and benefits. &lt;strong&gt;(Class of recommendation IIa, level of evidence B)&lt;/strong&gt; (Wallentin et al., 2000; Lagerqvist et al., 2006; Bach et al., 2004)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Gender&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Both genders should be evaluated and treated in the same way. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Berger et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Diabetic Patients&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All patients with NSTE-ACS should be screened for diabetes. Blood glucose levels should be monitored frequently in patients with known diabetes or admission hyperglycaemia. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Treatment of elevated blood glucose should avoid both excessive hyperglycaemia (10&amp;ndash;11 mmol/L [&amp;gt;180&amp;ndash;200 mg/dL]) and hypoglycaemia (&amp;lt;5 mmol/L [&amp;lt;90 mg/dL]). &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (De Caterina et al., 2010; NICE-SUGAR Study Investigators et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Antithrombotic treatment is indicated as in non-diabetic patients. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Renal function should be closely monitored following contrast exposure. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An early invasive strategy is recommended. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Wallentin et al., 2000; Cannon et al., 2001)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;DESs are recommended to reduce rates of repeat revascularization. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Task Force on Myocardial Revascularization of the ESC et al., 2010; Stettler et al., 2008)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;CABG surgery should be favoured over PCI in diabetic patients with main stem lesions and/or advanced multivessel disease. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Banning et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Patients with Chronic Kidney Disease (CKD)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Kidney function should be assessed by creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) in patients with NSTE-ACS, with special attention to elderly people, women, and patients with low body weight, as near normal serum creatinine levels may be associated with lower than expected CrCl and eGFR levels. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with NSTE-ACS and CKD should receive the same first-line antithrombotic treatment as patients devoid of CKD, with appropriate dose adjustments according to the severity of renal dysfunction. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Collet et al., 2005; Fox et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Depending on the degree of renal dysfunction, dose adjustment or switch to UFH with fondaparinux, enoxaparin, bivalirudin, as well as dose adjustment with small molecule GP IIb/IIIa receptor inhibitors are indicated. &lt;strong&gt;(Class of recommendation I, level of evidence B&lt;/strong&gt;) (Collet et al., 2005; Fox et al., 2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;UFH infusion adjusted to activated partial thromboplastin time (aPTT) is recommended when CrCl is &amp;lt;30 mL/min or eGFR is &amp;lt;30 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; with most anticoagulants (fondaparinux &amp;lt;20 mL/min). &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with NSTE-ACS and CKD considered for invasive strategy, hydration and low- or iso-osmolar contrast medium at low volume (&amp;lt;4 mL/kg) are recommended. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Task Force on Myocardial Revascularization of the ESC et al., 2010; Pannu, Wiebe, &amp;amp; Tonelli, 2006)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;CABG or PCI is recommended in patients with CKD amenable to revascularization after careful assessment of the risk&amp;ndash;benefit ratio in relation to the severity of renal dysfunction. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Szummer et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Patients with Heart Failure&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&amp;beta;-blockers and angiotensin-converting enzyme (ACE)-inhibitors/angiotensin receptor blockers (ARBs) appropriately titrated are indicated in patients with NSTE-ACS and LV dysfunction with or without signs of heart failure. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Dickstein et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Aldosterone inhibitors, preferably eplerenone, are indicated in patients with NSTE-ACS, LV dysfunction, and heart failure. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Dickstein et al., 2010; Pitt et al., 2003; Zannad et al., 2011)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with NSTE-ACS and LV dysfunction or heart failure are recommended to undergo coronary revascularization, if amenable to it. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Fox et al., 2010) &lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with NSTE-ACS and severe LV dysfunction should be considered after 1 month for device therapy (cardiac resynchronization therapy [CRT] and/or implantable cardioverter defibrillator) in addition to optimal medical therapy whenever indicated. &lt;strong&gt;(Class of recommendation IIa, level of evidence B)&lt;/strong&gt; (Dickstein et al., 2010; Moss et al., 2002)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Anaemia&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Low baseline haemoglobin is an independent marker of the risk of ischaemic and bleeding events and therefore haemoglobin measurement is recommended for risk stratification. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Sabatine et al., 2005; Bassand et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Blood transfusion is only recommended in the case of compromised haemodynamic status or haematocrit &amp;lt;25% or haemoglobin level &amp;lt;7 g/dL. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Hill et al., 2002)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Bleeding Complications&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Assessment of the individual bleeding risk is recommended on the basis of baseline characteristics (by use of risk scores), type, and duration of pharmacotherapy. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt; (Subherwal et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Drugs or combinations of drugs and non-pharmacological procedures (vascular access) known to carry a reduced risk of bleeding are indicated in patients at high risk of bleeding. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Stone et al., 2006; Agostoni et al., 2004; Alexander &amp;amp; Peterson, 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Interruption and/or neutralization of both anticoagulant and antiplatelet therapies is indicated in case of major bleeding, unless it can be adequately controlled by specific haemostatic measures. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Co-medication of proton pump inhibitors and antithrombotic agents is recommended in patients at increased risk of gastrointestinal haemorrhage. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (O'Donoghue et al., 2009; Abraham et al., 2010; Bhatt et al., 2010)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Minor bleeding should preferably be managed without interruption of active treatments. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Interruption of antiplatelet drugs and neutralization of their activity with platelet transfusion is recommended, depending on the drugs under consideration and the severity of bleeding. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Blood transfusion may have deleterious effects on outcome, and is therefore indicated only after individual assessment, but withheld in haemodynamically stable patients with haematocrit &amp;gt;25% or haemoglobin level &amp;gt;7 g/dL. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Hill et al., 2002; Rao et al., 2004)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Erythropoietin is not indicated as a treatment for anaemia or blood loss. &lt;strong&gt;(Class of recommendation III, level of evidence A)&lt;/strong&gt; (Singh et al., 2006)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Thrombocytopenia&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Immediate interruption of GP IIb/IIIa receptor inhibitors and/or heparin (UFH or LMWH) is indicated in the case of significant thrombocytopenia (&amp;lt;100 000/&amp;mu;L or &amp;gt;50% drop in platelet count) occurring during treatment. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Platelet transfusion with or without fibrinogen supplementation with fresh frozen plasma or cryoprecipitate in the case of bleeding is indicated in the case of severe thrombocytopenia (&amp;lt;10 000/&amp;mu;L) induced by GP IIb/IIIa receptor inhibitors. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Interruption of heparin (UFH or LMWH) is indicated in the case of documented or suspected heparin-induced thrombocytopenia (HIT), to be replaced by a direct thrombin inhibitor (DTI) in the case of thrombotic complications. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Anticoagulants with a low risk of HIT or devoid of risk of HIT (such as fondaparinux or bivalirudin) or brief administration of heparin (UFH or LMWH)&amp;mdash;in cases where these compounds are chosen as anticoagulant&amp;mdash;is recommended to prevent the occurrence of HIT. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Long-term Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations for Drugs in Secondary Prevention&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&amp;beta;-blockers are recommended in all patients with reduced LV systolic function (left ventricular ejection fraction [LVEF] &amp;le;40%). &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Lopez-Sendon et al., 2004)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ACE inhibitors are indicated within 24 h in all patients with LVEF &amp;le;40% and in patients with heart failure, diabetes, hypertension, or CKD, unless contraindicated. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Pfeffer et al., 1992; Torp-Pedersen &amp;amp; Kober, 1999)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ACE inhibitors are recommended for all other patients to prevent recurrence of ischaemic events, with preference given to agents and doses of proven efficacy. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Dagenais et al., 2006; Danchin et al., 2006)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ARBs are recommended for patients who are intolerant to ACE inhibitors, with preference given to agents and doses of proven efficacy. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (ONTARGET Investigators et al., 2008; Pfeffer et al., 2003)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Aldosterone blockade with eplerenone is indicated in patients after myocardial infarction (MI) who are already being treated with ACE inhibitors and &amp;beta;-blockers and who have an LVEF &amp;le;35% and either diabetes or heart failure, without significant renal dysfunction (serum creatinine &amp;gt;221 &amp;mu;mol/L [&amp;gt;2.5 mg/dL] for men and &amp;gt;177 &amp;mu;mol/L [&amp;gt;2.0 mg/dL] for women) or hyperkalaemia. &lt;strong&gt;(Class of recommendation I, level of evidence A)&lt;/strong&gt; (Pitt et al., 2003; Zannad et al., 2011)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Statin therapy with target low-density lipoprotein cholesterol (LDL-C) levels &amp;lt;1.8 mmol/L (&amp;lt;70 mg/dL) initiated early after admission is recommended. &lt;strong&gt;(Class of recommendation I, level of evidence B)&lt;/strong&gt; (Cannon et al., 2004)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Performance Measures&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for Performance Measures&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Development of regional and/or national programmes to measure performance indicators systematically and provide feedback to individual hospitals is recommended. &lt;strong&gt;(Class of recommendation I, level of evidence C)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Data derived from multiple randomized clinical trials or meta-analyses.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Data derived from a single randomized clinical trial or large non-randomized studies.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consensus of opinion of the experts and/or small studies, retrospective studies, registries.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Classes of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Classes of Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Classes of Recommendations&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Suggested Wording to Use&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Is recommended/is indicated&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class II&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;em&gt;Weight of evidence/opinion is in favour of usefulness/efficacy.&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Should be considered&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;em&gt;Class IIb&lt;/em&gt;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;em&gt;Usefulness/efficacy is less well established by evidence/opinion.&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;May be considered&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Is not recommended&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Algorithms are provided in the original guideline document for:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The spectrum of acute coronary syndrome (ACS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rapid rule-out of ACS with high-sensitivity troponin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Decision-making in ACS &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF, ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document [trunc]. Circulation. 2010 Dec 14;122(24):2619-33. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21060077&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Agostoni P, Biondi-Zoccai GG, de Benedictis ML, Rigattieri S, Turri M, Anselmi M, Vassanelli C, Zardini P, Louvard Y, Hamon M. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; Systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol. 2004 Jul 21;44(2):349-56. [48 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15261930&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Akkerhuis KM, Klootwijk PA, Lindeboom W, Umans VA, Meij S, Kint PP, Simoons ML. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies  patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients. Eur Heart J. 2001 Nov;22(21):1997-2006. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11603907&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM, American Heart Association Council on Clinical Cardiology, Society of Geriatric Cardiology. Acute coronary car. Circulation. 2007 May 15;115(19):2549-69. [127 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17502590&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Alexander KP, Peterson ED. Minimizing the risks of anticoagulants and platelet inhibitors. Circulation. 2010 May 4;121(17):1960-70. [112 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20439812&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Amsterdam EA, Kirk JD, Diercks DB, Lewis WR, Turnipseed SD. Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain. J Am Coll Cardiol. 2002 Jul 17;40(2):251-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12106928&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 May 30;373(9678):1849-60. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19482214&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996 Oct 31;335(18):1342-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8857017&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E. The effect of routine, early invasive management on outcome for elderly patients  with non-ST-segment elevation acute coronary syndromes. Ann Intern Med. 2004 Aug 3;141(3):186-95. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15289215&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, Dawkins KD, Serruys PW. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery  disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol. 2010 Mar 16;55(11):1067-75. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20079596&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bassand JP, Afzal R, Eikelboom J, Wallentin L, Peters R, Budaj A, Fox KA, Joyner CD, Chrolavicius S, Granger CB, Mehta S, Yusuf S, OASIS 5 and OASIS 6 Investigators. Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. Eur Heart J. 2010 Jan;31(1):50-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19825809&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, Simes RJ, White HD, Van de Werf F, Topol EJ, Hochman JS, Newby LK, Harrington RA, Califf RM, Becker RC, Douglas PS. Sex differences in mortality following acute coronary syndromes. JAMA. 2009 Aug 26;302(8):874-82. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19706861&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP, COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11;363(20):1909-17. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20925534&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients  undergoing coronary stent implantation. JAMA. 2010 Feb 24;303(8):754-62. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20179285&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G, GRACE Investigators. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest. 2004 Aug;126(2):461-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15302732&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 2. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-504. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15007110&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001 Jun 21;344(25):1879-87. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11419424&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Chang SA, Choi SI, Choi EK, Kim HK, Jung JW, Chun EJ, Kim KS, Cho YS, Chung WY, Youn TJ, Chae IH, Choi DJ, Chang HJ. Usefulness of 64-slice multidetector computed tomography as an initial diagnostic approach in patients with acute chest pain. Am Heart J. 2008 Aug;156(2):375-83. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18657674&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 Nov 5;366(9497):1622-32. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16271643&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997 Aug 14;337(7):447-52. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9250846&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, Lopez-Sendon J, Laufenberg CV, Klutman M, Gowda N, Gulba D, GRACE Investigators. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J. 2005 Nov;26(21):2285-93. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15932908&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left  ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006 Aug 12;368(9535):581-8. [16 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16905022&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med. 2006 Apr 10;166(7):787-96. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16606817&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;De Caterina R, Madonna R, Sourij H, Wascher T. Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. Eur Heart J. 2010 Jul;31(13):1557-64. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20519242&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, van Veldhuisen DJ, ESC Committee for Practice Guidelines (CPG), Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Document Reviewers, Tendera M, Anker SD, Blanc JJ, Gasparini M, Hoes AW, Israel CW, Kalarus Z, Merkely B, Swedberg K, Camm AJ. 2010 focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines [TRUNC]. Eur Heart J. 2010 Nov;31(21):2677-87. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20801924&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Diercks DB, Peacock WF, Hiestand BC, Chen AY, Pollack CV Jr, Kirk JD, Smith SC Jr, Gibler WB, Ohman EM, Blomkalns AL, Newby LK, Hochman JS, Peterson ED, Roe MT. Frequency and consequences of recording an electrocardiogram &gt;10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). Am J Cardiol. 2006 Feb 15;97(4):437-42. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16461033&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000 Jun 3;355(9219):1936-42. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10859038&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006 Apr 6;354(14):1464-76. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16537663&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Fox KA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, Valentin V, Moccetti T, Chrolavicius S, Afzal R, Yusuf S, OASIS 5 Investigators. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med. 2007 Sep 4;147(5):304-10. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17785485&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, Lagerqvist B, Wallentin L, FIR Collaboration. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010 Jun 1;55(22):2435-45. [26 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20359842&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, Avezum A, Goodman SG, Flather MD, Anderson FA Jr, Granger CB. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006 Nov 25;333(7578):1091. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17032691&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;FUTURA/OASIS-8 Trial Group, Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, Lopez-Sendon JL, Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B, Joyner C, Pogue J, Yusuf S. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010 Sep 22;304(12):1339-49. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20805623&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK, EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009 May 21;360(21):2176-90. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19332455&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev. 2010;(5):CD004587. [99 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20464732&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med. 1997 Dec 4;337(23):1648-53. [30 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9385123&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg G, Guyatt GH, Goodman SG. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines  (8th Edition). Chest. 2008 Jun;133(6 Suppl):670S-707S. [163 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18574276&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hasin Y, Danchin N, Filippatos GS, Heras M, Janssens U, Leor J, Nahir M, Parkhomenko A, Thygesen K, Tubaro M, Wallentin LC, Zakke I, Working Group on Acute Cardiac Care of the European Society of Cardiology. Recommendations for the structure, organization, and operation of intensive cardiac care units. Eur Heart J. 2005 Aug;26(16):1676-82. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15781435&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011 Feb 8;57(6):672-84. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21194870&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hill SR, Carless PA, Henry DA, Carson JL, Hebert PC, McClelland DB, Henderson KM. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2002;(2):CD002042. [65 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12076437&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):188S-203S. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15383472&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hoffmann U, Bamberg F, Chae CU, Nichols JH, Rogers IS, Seneviratne SK, Truong QA, Cury RC, Abbara S, Shapiro MD, Moloo J, Butler J, Ferencik M, Lee H, Jang IK, Parry BA, Brown DF, Udelson JE, Achenbach S, Brady TJ, Nagurney JT. Coronary computed tomography angiography for early triage of patients with acute  chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol. 2009 May 5;53(18):1642-50. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19406338&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hollander JE, Chang AM, Shofer FS, Collin MJ, Walsh KM, McCusker CM, Baxt WG, Litt HI. One-year outcomes following coronary computerized tomographic angiography for evaluation of emergency department patients with potential acute coronary syndrome. Acad Emerg Med. 2009 Aug;16(8):693-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19594460&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M, BASKET-PROVE Study Group. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med. 2010 Dec 9;363(24):2310-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21080780&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger PB, Schomig A. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006 Apr 5;295(13):1531-8. [41 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16533938&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S, Warnholtz A, Frohlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB, Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ, Munzel TF, Blankenberg S. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009 Aug 27;361(9):868-77. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19710485&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kwong RY, Schussheim AE, Rekhraj S, Aletras AH, Geller N, Davis J, Christian TF, Balaban RS, Arai AE. Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. Circulation. 2003 Feb 4;107(4):531-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12566362&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E, Wallentin L, Fast Revascularisation during InStability in Coronary artery disease (FRISC-II). 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet. 2006 Sep 16;368(9540):998-1004. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16980115&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lev EI, Battler A, Behar S, Porter A, Haim M, Boyko V, Hasdai D. Frequency, characteristics, and outcome of patients hospitalized with acute coronary syndromes with undetermined electrocardiographic patterns. Am J Cardiol. 2003 Jan 15;91(2):224-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12521637&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet. 1999 Aug 28;354(9180):701-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10475180&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004 Aug;25(15):1341-62. [229 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15288162&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet. 1996 Mar 2;347(9001):561-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8596317&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol. 1987 Jul 15;60(2):18A-25A. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2887097&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010 Oct 16;376(9749):1312-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20801494&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, Afzal R, Chrolavicius S, Jolly SS, Widimsky P, Avezum A, Rupprecht HJ, Zhu J, Col J, Natarajan MK, Horsman C, Fox KA, Yusuf S, TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009 May 21;360(21):2165-75. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19458363&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S, CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010 Oct 9;376(9748):1233-43. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20817281&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA, Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE). Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001 Aug 18;358(9281):527-33. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11520521&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Meijboom WB, Mollet NR, Van Mieghem CA, Weustink AC, Pugliese F, Van Pelt N, Cademartiri F, Vourvouri E, De Jaegere P, Krestin GP, De Feyter PJ. 64-Slice CT coronary angiography in patients with non-ST elevation acute coronary syndrome. Heart. 2007 Nov;93(11):1386-92. [23 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17344332&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J. 1985 Mar;6(3):199-226. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2863148&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Miller CD, Roe MT, Mulgund J, Hoekstra JW, Santos R, Pollack CV Jr, Ohman EM, Gibler WB, Peterson ED. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med. 2007 Aug;120(8):685-92. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17679127&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, Slama M, Milleron O, Collet JP, Henry P, Beygui F, Drouet L, ALBION Trial Investigators. A ra. J Am Coll Cardiol. 2006 Sep 5;48(5):931-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16949482&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002 Mar 21;346(12):877-83. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11907286&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP, Schmitt C, Seyfarth M, Dirschinger J, Schomig A. Evaluation of prolonged antithrombotic pretreatment (&quot;cooling-off&quot; strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA. 2003 Sep 24;290(12):1593-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14506118&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19318384&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Nyman I, Wallentin L, Areskog M, Areskog NH, Swahn E. Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group. Int J Cardiol. 1993 May;39(2):131-42. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8314646&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;O'Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MS. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008 Jul 2;300(1):71-80. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18594042&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009 Sep 19;374(9694):989-97. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19726078&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18378520&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Pannu N, Wiebe N, Tonelli M, Alberta Kidney Disease Network. Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006 Jun 21;295(23):2765-79. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16788132&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004 Jul 7;292(1):89-96. [24 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15238596&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669-77. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1386652&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 13;349(20):1893-906. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14610160&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348(14):1309-21. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12668699&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ, GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011 Mar 16;305(11):1097-105. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21406646&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. ISIS-1 (First International Study of Infarct Survival Collaborative Group. Lancet. 1986 Jul 12;2(8498):57-66. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2873379&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, Stamler JS, Califf RM. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004 Oct 6;292(13):1555-62. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15467057&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009 Aug 27;361(9):858-67. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19710484&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rubinshtein R, Halon DA, Gaspar T, Jaffe R, Karkabi B, Flugelman MY, Kogan A, Shapira R, Peled N, Lewis BS. Usefulness of 64-slice cardiac computed tomographic angiography for diagnosing acute coronary syndromes and predicting clinical outcome in emergency department patients with chest pain of uncertain origin. Circulation. 2007 Apr 3;115(13):1762-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17372178&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, Gibson CM, Braunwald E. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005 Apr 26;111(16):2042-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15824203&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Scirica BM, Morrow DA, Budaj A, Dalby AJ, Mohanavelu S, Qin J, Aroesty J, Hedgepeth CM, Stone PH, Braunwald E. Ischemia de. J Am Coll Cardiol. 2009 Apr 21;53(16):1411-21. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19371824&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW, Ruzyllo W, Umans VA, Vahanian A, Van De Werf F, Zeymer U, PENTUA Investigators. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol. 2004 Jun 16;43(12):2183-90. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15193678&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085-98. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108343&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007 Aug;154(2):221-31. [53 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17643570&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tcheng JE, Mehran R, Lansky AJ, Grines CL, Stone GW. Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2010 Apr 6;55(14):1416-24. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20359590&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ, CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Nov 20;288(19):2411-20. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12435254&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Juni P. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ. 2008;337:a1331. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18757996&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD, ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007 Feb 14;297(6):591-602. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17299194&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM, ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006 Nov 23;355(21):2203-16. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17124018&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007 Mar 17;369(9565):907-19. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17368152&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, Pollack CV Jr, Peterson ED, Alexander KP. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009 Apr 14;119(14):1873-82. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19332461&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, Wallentin L, Jernberg T, SWEDEHEART. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated [trunc] . Circulation. 2009 Sep 8;120(10):851-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19704097&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC), and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions, Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010 Oct;31(20):2501-55. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20802248&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N. Universal definition of myocardial infarction. Circulation. 2007 Nov 27;116(22):2634-53. [87 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17951284&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, Lindahl B, Giannitsis E, Hasin Y, Galvani M, Tubaro M, Alpert JS, Biasucci LM, Koenig W, Mueller C, Huber K, Hamm C, Jaffe AS, Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J. 2010 Sep;31(18):2197-204. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20685679&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced  left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet. 1999 Jul 3;354(9172):9-12. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10406358&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AW, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19755402&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19717846&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast revascularisation during instability in coronary artery disease. Lancet. 2000 Jul 1;356(9223):9-16. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10892758&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Weber M, Bazzino O, Navarro Estrada JL, de Miguel R, Salzberg S, Fuselli JJ, Liebetrau C, Woelken M, Moellmann H, Nef H, Hamm C. Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome. Am Heart J. 2011 Jul;162(1):81-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21742093&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW. Safety and effica. J Am Coll Cardiol. 2008 Sep 2;52(10):807-14. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18755342&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001-15. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17982182&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345(7):494-502. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11519503&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011 Jan 6;364(1):11-21. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21073363&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate management of patients with non-ST-segment elevation acute coronary syndromes that may help to improve both immediate and long-term outcomes&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Nitrates&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Side effects include headache and hypotension. A limitation of continuous nitrate therapy is the phenomenon of tolerance, which is related to both the dose administered and the duration of treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Calcium Channel Blockers&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Atrioventricular block may be induced by non-dihydropyridines &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) stopped early because of an excess of reinfarctions with nifedipine compared with metoprolol. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Antiplatelet and Anticoagulant Drugs&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Antiplatelet and anticoagulant agents may cause bleeding complications. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the acute coronary syndrome (ACS) setting, there are two main types of drug-induced thrombocytopenia, i.e., heparin-induced thrombocytopenia (HIT) and GP IIb/IIIa receptor inhibitor-induced thrombocytopenia, with a different prognosis for each type. In a meta-analysis, the use of GP IIb/IIIa receptor inhibitors was associated with an increase in major bleeding complications, but intracranial bleeding was not significantly increased. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the Pentasaccharide in Unstable Angina (PENTUA) study, abrupt vessel closure and unexpected angiographic thrombus tended to occur more frequently in the two fondaparinux groups compared with the unfractionated heparin (UFH) group. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Interruption of vitamin K antagonist (VKA) therapy may expose the patient to an increased risk of thrombo-embolic episodes. Interventions such as angiography, PCI, or CABG may be delicate or impossible to perform under full VKA anticoagulation; and long-term exposure of patients to triple therapy is clearly associated with a high risk of bleeding. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Aspirin&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A daily maintenance dose of 75&amp;ndash;100 mg of aspirin carries a lower risk of gastrointestinal intolerance than higher doses. Allergic responses to aspirin (anaphylactic shock, skin rash, and asthmatic reactions) are rare (&amp;lt;0.5%).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;P2Y&lt;sub&gt;12&lt;/sub&gt; Inhibitors&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;An increase in the rate of major bleeding was observed in clopidogrel-treated patients. In addition to bleeding, gastrointestinal disturbances (diarrhoea, abdominal discomfort) and rash are occasional adverse effects of clopidogrel. Thrombotic thrombocytopenic purpura and blood dyscrasias occur rarely. Clopidogrel desensitization is an option to treat clopidogrel allergy. Strong inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin) of CYP3A4 can significantly reduce or increase, respectively, the inhibitory effect of clopidogrel. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the TRITON study, life-threatening bleeding was significantly increased under prasugrel, with 1.4% vs. 0.9% (HR 1.52; 95% CI 1.08&amp;ndash;2.13; P = 0.01), as well as fatal bleeding, with 0.4% vs. 0.1% (HR 4.19; 95% CI 1.58&amp;ndash;11.11; P = 0.002) with prasugrel compared with clopidogrel. There was evidence of net harm with prasugrel in patients with a history of cerebrovascular events. Thrombocytopenia occurred at the same frequency in each group (0.3%) while neutropenia was less common with prasugrel (&amp;lt;0.1% vs. 0.2%; P = 0.02). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In addition to increased rates of minor or non-coronary artery bypass graft (CABG)-related major bleeding with ticagrelor, adverse effects include dyspnoea, increased frequency of ventricular pauses, and asymptomatic increases in uric acid. The dyspnoea induced by ticagrelor occurs most frequently (up to 15%) within the first week of treatment and may be transient or persist until cessation of treatment, but only infrequently is it severe enough to cause discontinuation of treatment. Ventricular pauses associated with ticagrelor mostly consist of asymptomatic nocturnal sinoatrial pauses; caution is advised in patients with either advanced sinoatrial disease or second- or third-degree atrioventricular block, unless already treated by permanent pacemaker. Rates of gastrointestinal disturbance and rash are similar with ticagrelor compared with clopidogrel. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Subgroups Most Likely to Be Harmed&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with chronic kidney disease (CKD) are at risk of contrast-induced nephropathy. This risk is increased in patients with older age and diabetes. In the case of urgent angiography the risk of contrast-induced nephropathy must be balanced against the ischaemic risk. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The applicability of findings from clinical trials to elderly patients encountered in routine clinical practice may be questionable. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Nitrates should not be given to patients on phosphodiesterase-5 inhibitors (sildenafil, vardenafil, or tadalafil) because of the risk of profound vasodilatation and critical blood pressure drop. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pre-treatment with a triple or dual antiplatelet regimen should be considered as only a relative contraindication to early bypass surgery, but does require specific surgical measures to minimize bleeding. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Many drugs with exclusive or substantial renal elimination need to be down-titrated or might even be contraindicated in chronic kidney disease (CKD) patients, including enoxaparin, fondaparinux, bivalirudin, and small-molecule glycoprotein (GP) IIb/IIIa receptor inhibitors (see Table 10 in the original guideline document).&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The European Society of Cardiology (ESC) Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgment. The guidelines do not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patients, in consultation with that patient, and where appropriate and necessary the patient's guardian or carer. It is also the health professional's responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Guidelines are no substitutes but are complements for textbooks and cover the ESC Core Curriculum topics. Guidelines and recommendations should help the physicians to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible physician(s). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The task of developing European Society of Cardiology (ESC) Guidelines covers not only the integration of the most recent research, but also the creation of educational tools and implementation programmes for the recommendations. To implement the guidelines, condensed pocket guidelines versions, summary slides, booklets with essential messages, and an electronic version for digital applications (smartphones, etc.) are produced. These versions are abridged and, thus, if needed, one should always refer to the full text version, which is freely available on the ESC website. The National Societies of the ESC are encouraged to endorse, translate, and implement the ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Surveys and registries are needed to verify that real-life daily practice is in keeping with what is recommended in the guidelines, thus completing the loop between clinical research, writing of guidelines, and implementing them in clinical practice.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Foreign Language Translations" /><FieldValue Value="Mobile Device Resources" /><FieldValue Value="Pocket Guide/Reference Cards" /><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Resources" /><FieldValue Value="Slide Presentation" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Timeliness " /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011 Dec;32(23):2999-3054. [320 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21873419&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2000 Sep (revised 2011 Dec)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="European Society of Cardiology - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Task Force received its entire financial support from the European Society of Cardiology without any involvement from the healthcare industry.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-segment Elevation&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Task Force Members&lt;/em&gt;: Christian W. Hamm (&lt;em&gt;Chairperson&lt;/em&gt;) (Germany), Jean-Pierre Bassand (&lt;em&gt;Co-Chairperson&lt;/em&gt;) (France), Stefan Agewall (Norway), Jeroen Bax (The Netherlands), Eric Boersma (The Netherlands), Hector Bueno (Spain), Pio Caso (Italy), Dariusz Dudek (Poland), Stephan Gielen (Germany), Kurt Huber (Austria), Magnus Ohman (USA), Mark C. Petrie (UK), Frank Sonntag (Germany), Miguel Sousa Uva (Portugal), Robert F. Storey (UK), William Wijns (Belgium), Doron Zahger (Israel)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;European Society of Cardiology (ESC) Committee for Practice Guidelines Members&lt;/em&gt;: Jeroen J. Bax (&lt;em&gt;Chairperson&lt;/em&gt;) (The Netherlands), Angelo Auricchio (Switzerland), Helmut Baumgartner (Germany), Claudio Ceconi (Italy), Veronica Dean (France), Christi Deaton (UK), Robert Fagard (Belgium), Christian Funck-Brentano (France), David Hasdai (Israel), Arno Hoes (The Netherlands), Juhani Knuuti (Finland), Philippe Kolh (Belgium), Theresa McDonagh (UK), Cyril Moulin (France), Don Poldermans (The Netherlands), Bogdan A. Popescu (Romania), eljko Reiner (Croatia), Udo Sechtem (Germany), Per Anton Sirnes (Norway), Adam Torbicki (Poland), Alec Vahanian (France), Stephan Windecker (Switzerland)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Document Reviewers&lt;/em&gt;: Stephan Windecker (&lt;em&gt;CPG Review Coordinator&lt;/em&gt;) (Switzerland), Stephan Achenbach (Germany), Lina Badimon (Spain), Michel Bertrand (France), Hans Erik B&amp;oslash;tker (Denmark), Jean-Philippe Collet (France), Filippo Crea, (Italy), Nicolas Danchin (France), Erling Falk (Denmark), John Goudevenos (Greece), Dietrich Gulba (Germany), Rainer Hambrecht (Germany), Joerg Herrmann (USA), Adnan Kastrati (Germany), Keld Kjeldsen (Denmark), Steen Dalby Kristensen (Denmark), Patrizio Lancellotti (Belgium), Julinda Mehilli (Germany), B&amp;eacute;la Merkely (Hungary), Gilles Montalescot (France), Franz-Josef Neumann (Germany), Ludwig Neyses (UK), Joep Perk (Sweden), Marco Roffi (Switzerland), Francesco Romeo (Italy), Mikhail Ruda (Russia), Eva Swahn (Sweden), Marco Valgimigli (Italy), Christiaan JM Vrints (Belgium), Petr Widimsky (Czech Republic)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The experts of the writing and reviewing panels filled in declarations of interest forms of all relationships which might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file and can be found on the &lt;a href=&quot;http://www.escardio.org/guidelines&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;European Society of Cardiology (ESC) Web site&lt;/a&gt;. Any changes in declarations of interest that arise during the writing period must be notified to the ESC and updated.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="159" OrdBy="1255" ID="453" Name="Guideline Endorser(s)" Type="orglist"><FieldValue Value="Belgian Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Belorussian Scientific Society of Cardiologists - Medical Specialty Society" /><FieldValue Value="Bulgarian Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Croatian Cardiac Society - Medical Specialty Society" /><FieldValue Value="Estonian Society of Cardiology - Medical Specialty Society" /><FieldValue Value="French Society of Cardiology - Medical Specialty Society" /><FieldValue Value="German Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Hellenic Cardiological Society - Medical Specialty Society" /><FieldValue Value="Hungarian Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Luxembourg Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Moldavian Society of Cardiology - Medical Specialty Society" /><FieldValue Value="National Society of Cardiology of the Former Yugoslav Republic of Macedonia - Medical Specialty Society" /><FieldValue Value="Netherlands Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Polish Cardiac Society - Medical Specialty Society" /><FieldValue Value="Portuguese Society of Cardiology - Medical Specialty Society" /><FieldValue Value="San Marino Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Slovak Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Slovenian Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Society of Cardiology of the Russian Federation - Medical Specialty Society" /><FieldValue Value="Spanish Society of Cardiology - Medical Specialty Society" /><FieldValue Value="Turkish Society of Cardiology - Medical Specialty Society" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W, ESC Committee for Practice Guidelines (CPG), Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Kristensen SD, Widimsky P, McGregor K, Sechtem U, Tendera M, Hellemans I, Gomez JL, Silber S, Funck-Brentano C, Kristensen SD, Andreotti F, Benzer W, Bertrand M, Betriu A, De Caterina R, DeSutter J, Falk V, Ortiz AF, Gitt A, Hasin Y, Huber K, Kornowski R, Lopez-Sendon J, Morais J, Nordrehaug JE, Silber S, Steg PG, Thygesen K, Tubaro M, Turpie AG, Verheugt F, Windecker S, Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007 Jul;28(13):1598-660.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/ACS-non-ST-segment-elevation.aspx&quot; title=&quot;ESC Web site&quot;&gt;European Society of Cardiology (ESC) Web site&lt;/a&gt;. Also available in &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/TranslatedGuidelinesDocuments/Guidelines-NSTEACS-Spanish-2011.pdf&quot; title=&quot;ESC Web site&quot;&gt;Spanish&lt;/a&gt; from the ESC Web site.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK, Tel: +44 (0) 1865 353263, Fax: +44 (0) 1865 353774, Web site: &lt;a href=&quot;http://www.eurheartj.oxfordjournals.org/&quot; title=&quot;European Heart Journal Web site&quot;&gt;http://www.eurheartj.oxfordjournals.org/&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Essential messages. 2011. 9 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/Essential%20Messages%20NSTE.pdf&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;European Society of Cardiology (ESC) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acute coronary syndromes in patients presenting without persistent ST-segment elevation. Pocket guidelines. Available for order from the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/products/pocket/Pages/ACS.aspx&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site&lt;/a&gt;. Also available for mobile download from the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/ACS-PDA.aspx&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation. Slide set. Electronic copies: Available for registered users from the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/ACS-non-ST-segment-elevation.aspx&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Addenda. 2011. 9 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/Guidelines-NSTE-ACS-appendix.pdf&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ESC webinar on non ST-segment elevation acute coronary syndromes: a clinical case based approach. Available from the &lt;a href=&quot;http://www.escardio.org/education/eLearning/webinars/general-cardiology/recordings/Pages/new-guidelines-non-ST-Segment-elevation-acs.aspx&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Webcast of the new ESC guidelines on non ST-segment elevation acute coronary syndromes presented at the ESC Congress 2011. Available from the &lt;a href=&quot;http://assets.escardio.org/webcasts/default.aspx?id=ESC2011/2070&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK, Tel: &lt;span class=&quot;baec5a81-e4d6-4674-97f3-e9220f0136c1&quot; style=&quot;white-space: nowrap;&quot;&gt;+44 (0) 1865 353263&lt;/span&gt;, Fax: &lt;span class=&quot;baec5a81-e4d6-4674-97f3-e9220f0136c1&quot; style=&quot;white-space: nowrap;&quot;&gt;+44 (0) 1865 353774&lt;/span&gt;, Web site: &lt;a href=&quot;http://www.eurheartj.org/&quot; title=&quot;European Heart Journal Web site&quot;&gt;http://www.eurheartj.org/&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Additionally, continuing medical education (CME) credit is available online at the &lt;a href=&quot;http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/NSTE_ACS%20CME%20Questions.aspx&quot; title=&quot;European Society of Cardiology (ESC) Web site&quot;&gt;ESC Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI on September 17, 2001. The information was verified by the guideline developer on September 27, 2001. This summary was updated by ECRI on April 16, 2003. This summary was updated by ECRI Institute on June 22, 2007 following the U.S. Food and Drug Administration (FDA) advisory on heparin sodium injection. This NGC summary was updated by ECRI Institute on October 4, 2007. The updated information was verified by the guideline developer on November 15, 2007. This summary was updated by ECRI Institute on March 14, 2008 following the updated FDA advisory on heparin sodium injection. This summary was updated by ECRI Institute on December 26, 2008 following the FDA advisory on Innohep (tinzaparin). This summary was updated by ECRI Institute on January 4, 2010 following the U.S. Food and Drug Administration advisory on Plavix (Clopidogrel). This summary was updated by ECRI Institute on May 17, 2010 following the U.S. Food and Drug Administration advisory on Plavix (clopidogrel). This summary was updated by ECRI Institute on July 26, 2010 following the U.S. Food and Drug Administration (FDA) advisory on Proton Pump Inhibitors (PPI). This summary was updated by ECRI Institute on July 27, 2010 following the FDA drug safety communication on Heparin. This summary was updated by ECRI Institute on June 27, 2011 following the U.S. Food and Drug Administration advisory on Zocor (simvastatin). This summary was updated by ECRI Institute on April 13, 2012 following the U.S. Food and Drug Administration advisories on Statin Drugs and Statins and HIV or Hepatitis C drugs. This summary was updated by ECRI Institute on April 29, 2013. The updated information was verified by the guideline developer on July 10, 2013. This summary was updated by ECRI Institute on March 10, 2014 following the U.S. Food and Drug Administration advisory on Low Molecular Weight Heparins.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary is based on the original guideline, which is subject to the guideline developer's restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
